New members joined the RDAF in May 2018

    4 Jun, 2018

    In May 2018, Swedish Orphan Biovitrum, a company specialized in the area of rare diseases, the Swiss umbrella patient organization ProRaris and the Swiss Foundation for Research on Muscle Diseases (SSEM/FSRMM) became members of the Rare Disease Action Forum (RDAF). In total, the Forum now hosts fifteen members who represent major groups of stakeholders in the area of rare diseases including industry, patient organizations, healthcare organizations, physicians and foundations for research. With its increased membership, the RDAF reinforces its contribution towards the development of sustainable solutions that improve the situation of patients with rare diseases in Switzerland.

    Continue reading

    Joint statement on the KVV/OAMal and KLV/OPAS revision

    The RDAF co-signed a joint statement with other stakeholders on the revision of the Health Insurance Ordinance (KVV/OAMal) and Health Benefits Ordinance (KLV/OPAS). The statement highlights the potential negative impacts of the revision, including the following: -...